Cleaning Companies Deal With New Challenges Amid Coronavirus #CoronavirusUpdates
To reduce the risk of contracting coronavirus, many of us have become obsessed with washing our hands and disinfecting high-touch surfaces. And while the pursuit of these ultra-sanitary conditions is leading to steady work for several professional cleaning companies, it can place workers in a potentially dangerous situation. Professional cleaners with All Bright Services wore masks and gloves Wednesday as they scrubbed Murray’s Cheese on Bleecker Street in the West Village to make sure there was no trace of the coronavirus. "It's a little risky, and yes, I do have minor concerns, but I make sure I protect myself, always use the right chemicals," said worker Jamek Willis. Willis worked with his team on a cleanup job that lasted more than seven hours. "We get all the corners, top, bottom, inside out, cabinets, doors, handles," he said. "Anything you need, we wipe down. Sanitize!" So far, Willis says all of the assignments that his cleaning crews has received during the pandemic have been precautionary. Yet he is fully aware that he could one day have to sanitize a workspace where coronavirus was lurking. "I guess there’s fear in everything, but it’s a job," he said. "We come in with faith, with protection, and we gotta do the job. But when we cross that threshold, we'll see." The cleaning crew at Murray's Cheese says during the coronavirus pandemic, work has been steady but not booming. Still, they are grateful to have a job and steady work. That's an enviable position that some cleaning companies wish they could provide for their employees. "I can't bill clients into April because we won't be cleaning them in April," said Claudette Robb Ross, the owner of NYC's Best Commercial Cleaning Service, Inc., which is based in Manhattan. "I bill them at the beginning of the month.” As a result of Governor Andrew Cuomo's mandate last week that all non-essential workers stay at home, Robb Ross says none of her clients need their offices cleaned. And in just a few days, she fears she will need to lay off all five of her employees. "The end of this month ends it for everyone," she says, "and they will get in line for unemployment like a few million others." http://videomarketingservices.net/ https://www.youtube.com/channel/UCR0k7hsqw3CkcdTQ-d1_1-g https://nationalcoronaviruscleanup.blogspot.com/ https://nationalcoronaviruscleanup.wordpress.com/ https://nationalcoronaviruscleanup.tumblr.com/ https://medium.com/@nationalcoronaviruscleanup https://www.pinterest.com/nationalcoronaviruscleanup/ #NationalCoronavirusCleanup #CoronavirusNews #Covid19Updates
https://www.youtube.com/watch?v=8K5BxMbxQDQ
Monday, April 6, 2020
India bans exports of drug touted by Trump as potential Covid-19 treatment #CoronavirusUpdates
India bans exports of drug touted by Trump as potential Covid-19 treatment #CoronavirusUpdates
The Indian government has banned exports of hydroxychloroquine, the decades-old malaria drug that was touted by President Trump as a possible weapon in the fight against Covid-19, but has been in short supply. In a notice posted Wednesday, the Directorate General of Foreign Trade prohibited the medicine and any formulations from being shipped outside of the country, except for companies that must fulfill existing contracts and on humanitarian grounds that would have to be approved on a case-by-case basis by the Ministry of External Affairs. The move comes amid heightened speculation over the extent to which the drug can be effective in combating the novel coronavirus, since clinical trials have not been conducted for use in Covid-19 patients. The drug, which is also approved to treat lupus and rheumatoid arthritis, is among four medicines that will be the focus of a large study announced last week by the World Health Organization. In recent weeks, the medicine was the subject of several medical papers suggesting a degree of effectiveness in Covid-19 patients, prompting doctors to write prescriptions and hospitals in the U.S. to place orders. Last Friday, after Trump talked up the drug, 1.5 million tablets were been ordered, but just 12% of orders were filled. Orders have jumped 2,196% since the pandemic was declared. Related: Hospital orders for old malaria drugs have spiked amid coronavirus pandemic Over the past few days, state pharmacy boards in Texas, Ohio, Idaho, and Nevada began restricting who can be prescribed the drugs, after reports of some doctors prescribing the drugs for themselves and their families. Consequently, shortages were reported by the American Society of Health-System Pharmacists, although four manufacturers have since pledged to produce millions of tablets. Among them are Mylan, Teva Pharmaceuticals, and the Sandoz unit of Novartis. Spokespeople for Mylan, Novartis and Teva wrote us that their companies produce hydroxylcholoroquine in U.S. facilities. http://videomarketingservices.net/ https://www.youtube.com/channel/UCR0k7hsqw3CkcdTQ-d1_1-g https://nationalcoronaviruscleanup.blogspot.com/ https://nationalcoronaviruscleanup.wordpress.com/ https://nationalcoronaviruscleanup.tumblr.com/ https://medium.com/@nationalcoronaviruscleanup https://www.pinterest.com/nationalcoronaviruscleanup/ To fill the void, though, the Food and Drug Administration late last week also took the unusual step of lifting an import ban that was placed in 2015 on Ipca Laboratories, an Indian drug maker that was cited for poor manufacturing practices at three facilities, so that the company could export hydroxychloroquine and the required active pharmaceutical ingredients to make the medicine. For now, the company does not expect to be able to export. “As the things stand today, we can not export the API hydroxychloroquine sulphate, as well as it’s formulations, unless exemptions are given on a case to case basis on humanitarian grounds,” Harish Kamath, the IPCA corporate counsel wrote us #NationalCoronavirusCleanup #CoronavirusNews #Covid-19Updates
https://www.youtube.com/watch?v=3GTNuMpZaZQ
The Indian government has banned exports of hydroxychloroquine, the decades-old malaria drug that was touted by President Trump as a possible weapon in the fight against Covid-19, but has been in short supply. In a notice posted Wednesday, the Directorate General of Foreign Trade prohibited the medicine and any formulations from being shipped outside of the country, except for companies that must fulfill existing contracts and on humanitarian grounds that would have to be approved on a case-by-case basis by the Ministry of External Affairs. The move comes amid heightened speculation over the extent to which the drug can be effective in combating the novel coronavirus, since clinical trials have not been conducted for use in Covid-19 patients. The drug, which is also approved to treat lupus and rheumatoid arthritis, is among four medicines that will be the focus of a large study announced last week by the World Health Organization. In recent weeks, the medicine was the subject of several medical papers suggesting a degree of effectiveness in Covid-19 patients, prompting doctors to write prescriptions and hospitals in the U.S. to place orders. Last Friday, after Trump talked up the drug, 1.5 million tablets were been ordered, but just 12% of orders were filled. Orders have jumped 2,196% since the pandemic was declared. Related: Hospital orders for old malaria drugs have spiked amid coronavirus pandemic Over the past few days, state pharmacy boards in Texas, Ohio, Idaho, and Nevada began restricting who can be prescribed the drugs, after reports of some doctors prescribing the drugs for themselves and their families. Consequently, shortages were reported by the American Society of Health-System Pharmacists, although four manufacturers have since pledged to produce millions of tablets. Among them are Mylan, Teva Pharmaceuticals, and the Sandoz unit of Novartis. Spokespeople for Mylan, Novartis and Teva wrote us that their companies produce hydroxylcholoroquine in U.S. facilities. http://videomarketingservices.net/ https://www.youtube.com/channel/UCR0k7hsqw3CkcdTQ-d1_1-g https://nationalcoronaviruscleanup.blogspot.com/ https://nationalcoronaviruscleanup.wordpress.com/ https://nationalcoronaviruscleanup.tumblr.com/ https://medium.com/@nationalcoronaviruscleanup https://www.pinterest.com/nationalcoronaviruscleanup/ To fill the void, though, the Food and Drug Administration late last week also took the unusual step of lifting an import ban that was placed in 2015 on Ipca Laboratories, an Indian drug maker that was cited for poor manufacturing practices at three facilities, so that the company could export hydroxychloroquine and the required active pharmaceutical ingredients to make the medicine. For now, the company does not expect to be able to export. “As the things stand today, we can not export the API hydroxychloroquine sulphate, as well as it’s formulations, unless exemptions are given on a case to case basis on humanitarian grounds,” Harish Kamath, the IPCA corporate counsel wrote us #NationalCoronavirusCleanup #CoronavirusNews #Covid-19Updates
https://www.youtube.com/watch?v=3GTNuMpZaZQ
Friday, April 3, 2020
Vir Biotechnology reports early progress in antibody treatment for Covid-19 #CoronavirusUpdates
Vir Biotechnology reports early progress in antibody treatment for Covid-19 #CoronavirusUpdates
Vir Biotechnology, a San Francisco-based biotechnology firm, said Wednesday that laboratory testing showed two of its antibody drugs appeared to neutralize the coronavirus that causes Covid-19 and that it would pursue testing them in people. The company said that human tests of the drugs could begin in three to five months, putting it roughly in line with two other efforts to produce anti-coronavirus antibodies. Regeneron, based in Tarrytown, N.Y., has said that its antibodies could enter trials by early summer — and that its treatment, if it proves effective, could be available for some uses in the fall. Eli Lilly, which is developing anti-SARS-CoV-2 antibodies with AbCellera, a Vancouver biotech, has said it hopes to begin human tests in four months. “Stopping this disease will take a combination of prevention and treatment approaches,” Vir CEO George Scangos said in a statement. http://videomarketingservices.net/ https://www.youtube.com/channel/UCR0k7hsqw3CkcdTQ-d1_1-g https://nationalcoronaviruscleanup.blogspot.com/ https://nationalcoronaviruscleanup.wordpress.com/ https://nationalcoronaviruscleanup.tumblr.com/ https://medium.com/@nationalcoronaviruscleanup https://www.pinterest.com/nationalcoronaviruscleanup/ “At Vir, we are fortunate that our existing antibody platform gave us a running start against COVID-19, and we have the internal and partnered capabilities to work on multiple approaches.” #NationalCoronavirusCleanup #CoronavirusNews #Covid-19Updates
https://www.youtube.com/watch?v=ryid_88ylig
Vir Biotechnology, a San Francisco-based biotechnology firm, said Wednesday that laboratory testing showed two of its antibody drugs appeared to neutralize the coronavirus that causes Covid-19 and that it would pursue testing them in people. The company said that human tests of the drugs could begin in three to five months, putting it roughly in line with two other efforts to produce anti-coronavirus antibodies. Regeneron, based in Tarrytown, N.Y., has said that its antibodies could enter trials by early summer — and that its treatment, if it proves effective, could be available for some uses in the fall. Eli Lilly, which is developing anti-SARS-CoV-2 antibodies with AbCellera, a Vancouver biotech, has said it hopes to begin human tests in four months. “Stopping this disease will take a combination of prevention and treatment approaches,” Vir CEO George Scangos said in a statement. http://videomarketingservices.net/ https://www.youtube.com/channel/UCR0k7hsqw3CkcdTQ-d1_1-g https://nationalcoronaviruscleanup.blogspot.com/ https://nationalcoronaviruscleanup.wordpress.com/ https://nationalcoronaviruscleanup.tumblr.com/ https://medium.com/@nationalcoronaviruscleanup https://www.pinterest.com/nationalcoronaviruscleanup/ “At Vir, we are fortunate that our existing antibody platform gave us a running start against COVID-19, and we have the internal and partnered capabilities to work on multiple approaches.” #NationalCoronavirusCleanup #CoronavirusNews #Covid-19Updates
https://www.youtube.com/watch?v=ryid_88ylig
Subscribe to:
Posts (Atom)